Delphinidin attenuates neoplastic transformation in JB6 Cl41 mouse epidermal cells by blockingraf/mitog en-activated protein kinase kinase/extracellular signal-regulated kinase signaling

Cancer Prevention Research

Volumn 1, Issue 7, 2008, Pages 522-531

  Kang, Nam Joo ^a,b   Lee, Ki Won ^a,c   Kwon, Jung Yeon ^b,c   Hwang, Mun Kyung ^b,c   Rogozin, Evgeny A ^a   Heo, Yong Seok ^c   Bode, Ann M ^a   Lee, Hyong Joo ^b   Dong, Zigang ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Seoul National University   (South Korea)

^c Konkuk University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHOCYANIN; CYCLOOXYGENASE 2; DELPHINIDIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; RAF PROTEIN;

ANIMAL; ARTICLE; CELL LINE; CELL TRANSFORMATION; DRUG EFFECT; EPITHELIUM CELL; GENE EXPRESSION; MOUSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; ANTHOCYANINS; BLOTTING, WESTERN; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; CYCLOOXYGENASE 2; EPITHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; RAF KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 62349121095     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0071     Document Type: Article

References (42)

1. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow. Lancet 2001;357:539-45.
2. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
3. Higashi Y, Kanekura T, Kanzaki T. Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: evidence for growth suppression by inhibiting COX-2 expression. Int J Cancer 2000;86:667-71.
4. Lee JL, Mukhtar H, Bickers DR, Kopelovich L, Athar M. Cyclooxygenases in the skin: pharmacological and toxicological implications. Toxicol Appl Pharmacol 2003;192:294-306.
5. Williams CS, DuBois RN. Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol 1996;270:G393-400.
6. Liu G, Bode A, Ma WY, Sang S, Ho CT, Dong Z. Two novel glycosides from the fruits of Morinda citrifolia (noni) inhibit AP-1 transactivation and cell transformation in the mouse epidermal JB6 cell line. Cancer Res 2001;61:5749-56.
7. 2-terminal kinase. Gastroenterology 2004;126:136-47.
8. Dong Z, Birrer MJ, Watts RG, Matrisian LM, Colburn NH. Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proc Natl Acad Sci U S A 1994;91:609-13.
9. Huang C, Ma WY, Young MR, Colburn N, Dong Z. Shortage of mitogen-activated protein kinase is responsible for resistance to AP-1 transactivation and transformation in mouse JB6 cells. Proc Natl Acad Sci U S A 1998;95:156-61.
10. Young MR, Li JJ, Rincon M, et al. Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. Proc Natl Acad Sci U S A 1999;96:9827-32.
11. Sebolt-Leopold JS, Herrera R. Targeting the mitogen- activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004;4:937-47.
12. Nomura M, Ichimatsu D, Moritani S, et al. Inhibition of epidermal growth factor-induced cell transformation and Akt activation by caffeine. Mol Carcinog 2005;44:67-76.
13. Suzukawa K, Weber TJ, Colburn NH. AP-1, NF-κ- B, and ERK activation thresholds for promotion of neoplastic transformation in the mouse epidermal JB6 model. Environ Health Perspect 2002;110: 865-70.
14. Roberts PJ, Der CJ. Targeting the Raf-MEKERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26: 3291-310.
15. Thompson N, Lyons J. Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol 2005;5:350-6.
16. Schreck R, Rapp UR. Raf kinases: oncogenesis and drug discovery. Int J Cancer 2006;119: 2261-71.
17. Gioeli D, Mandell JW, Petroni GR, Frierson HF, Jr., Weber MJ. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 1999;59:279-84.
18. Oka H, Chatani Y, Hoshino R, et al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res 1995;55:4182-7.
19. Mazza G. Anthocyanins in grapes and grape products. Crit Rev Food Sci Nutr 1995;35:341-71.
20. Chen S, Ruan Q, Bedner E, et al. Effects of the flavonoid baicalin and its metabolite baicalein on androgen receptor expression, cell cycle progression and apoptosis of prostate cancer cell lines. Cell Prolif 2001;34:293-304.
21. Fotsis T, Pepper MS, Aktas E, et al. Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Res 1997;57:2916-21.
22. Nagase H, Sasaki K, Kito H, Haga A, Sato T. Inhibitory effect of delphinidin from Solanum melongena on human fibrosarcoma HT-1080 invasiveness in vitro. Planta Med 1998;64:216-9.
23. Hou DX, Kai K, Li JJ, et al. Anthocyanidins inhibit activator protein 1 activity and cell transformation: structure-activity relationship and molecular mechanisms. Carcinogenesis 2004;25:29-36.
24. Subbaramaiah K, Bulic P, Lin Y, Dannenberg AJ, Pasco DS. Development and use of a gene promoter- based screen to identify novel inhibitors of cyclooxygenase- 2 transcription. J Biomol Screen 2001;6:101-10.
25. Wang Y, Falasca M, Schlessinger J, et al. Activation of the c-fos serum response element by phosphatidyl inositol 3-kinase and rho pathways in HeLa cells. Cell Growth Differ 1998;9:513-22.
26. Wang Y, Prywes R. Activation of the c-fos enhancer by the erk MAP kinase pathway through two sequence elements: the c-fos AP-1 and p62TCF sites. Oncogene 2000;19:1379-85.
27. Bode AM, Dong Z. Signal transduction pathways: targets for chemoprevention of skin cancer. Lancet Oncol 2000;1:181-8.
28. Bode AM, Dong Z. Signal transduction pathways in cancer development and as targets for cancer prevention. Prog Nucleic Acid Res Mol Biol 2005; 79:237-97.
29. Muth ER, Laurent JM, Jasper P. The effect of bilberry nutritional supplementation on night visual acuity and contrast sensitivity. Altern Med Rev 2000;5:164-73.
30. Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992;339:1523-6.
31. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 1998;12:1063-73.
32. Prosperi JR, Mallery SR, Kigerl KA, Erfurt AA, Robertson FM. Invasive and angiogenic phenotype of MCF-7 human breast tumor cells expressing human cyclooxygenase-2. Prostaglandins Other Lipid Mediat 2004;73:249-64.
33. Liu G, Ma WY, Bode AM, Zhang Y, Dong Z. NS- 398 and piroxicam suppress UVB-induced activator protein 1 activity by mechanisms independent of cyclooxygenase-2. J Biol Chem 2003;278: 2124-30.
34. Hsu TC, Young MR, Cmarik J, Colburn NH. Activator protein 1 (AP-1)- and nuclear factor κB (NF-κB)-dependent transcriptional events in carcinogenesis. Free Radic Biol Med 2000;28:1338-48.
35. Cowley S, Paterson H, Kemp P, Marshall CJ. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 1994;77:841-52.
36. Sebolt-Leopold JS, Dudley DT, Herrera R, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999;5: 810-6.
37. Johnson JI, Decker S, Zaharevitz D, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001;84:1424-31.
38. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003;9:4227-39.
39. Brugge JS, Erikson RL. Identification of a transformation- specific antigen induced by an avian sarcoma virus. Nature 1977;269:346-8.
40. Collett MS, Erikson RL. Protein kinase activity associated with the avian sarcoma virus src gene product. Proc Natl Acad Sci U S A 1978;75:2021-4.
41. Mansour SJ, Matten WT, Hermann AS, et al. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 1994; 265:966-70.
42. Ohren JF, Chen H, Pavlovsky A, et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 2004;11:1192-7.